Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4161/hv.29754 http://scihub22266oqcxt.onion/10.4161/hv.29754 C4514080!4514080 !25483669     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25483669 &cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 217.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25483669 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Hum+Vaccin+Immunother 2014 ; 10 (11 ): 3165-74 Nephropedia Template TP {{tp|p=25483669 |t=2014. Engineering better immunotherapies via RNA interference |pdf=|usr=}}{{25483669 }} gab.com Text Engineering better immunotherapies via RNA interference JO: Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=25483669 #FOAvip The therapeutic potential of dendritic cell (DC) cancer vaccines has gained momentum in recent years. However, clinical data indicate that antitumor immune responses generally fail to translate into measurable tumor regression. This has been ascribed to a variety of tolerance mechanisms, one of which is the expression of immunosuppressive factors by DCs and T cells. With respect to cancer immunotherapies, these factors antagonise the ability to induce robust and sustained immunity required for tumor cell eradication. Gene silencing of immunosuppressive factors in either DCs or adoptive transferred T cells enhanced anti-tumor immune responses and significantly inhibited tumor growth. Therefore, engineered next generation of DC vaccines or adoptive T-cell therapy should include immunomodulatory siRNAs to release the "brakes" imposed by the immune system. Moreover, the combination of gene silencing, antigen targeting to DCs and cytoplasmic cargo delivery will improve clinical benefits. Twit Text FOAVip Engineering better immunotherapies via RNA interference ????Hum Vaccin Immunother http://www.kidney.de/pget.php?&tw=1&pmid=25483669 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25483669 #FOAvip English Wikipedia <ref>{{Cite pmid|25483669 }}</ref> Engineering better immunotherapies via RNA interference #MMPMID25483669 Sioud M Hum Vaccin Immunother 2014[]; 10 (11 ): 3165-74 PMID25483669 show ga The therapeutic potential of dendritic cell (DC) cancer vaccines has gained momentum in recent years. However, clinical data indicate that antitumor immune responses generally fail to translate into measurable tumor regression. This has been ascribed to a variety of tolerance mechanisms, one of which is the expression of immunosuppressive factors by DCs and T cells. With respect to cancer immunotherapies, these factors antagonise the ability to induce robust and sustained immunity required for tumor cell eradication. Gene silencing of immunosuppressive factors in either DCs or adoptive transferred T cells enhanced anti-tumor immune responses and significantly inhibited tumor growth. Therefore, engineered next generation of DC vaccines or adoptive T-cell therapy should include immunomodulatory siRNAs to release the "brakes" imposed by the immune system. Moreover, the combination of gene silencing, antigen targeting to DCs and cytoplasmic cargo delivery will improve clinical benefits. |Cancer Vaccines/*immunology/therapeutic use [MESH] |Dendritic Cells/*immunology/transplantation [MESH] |Humans [MESH] |Immunomodulation/*genetics/immunology [MESH] |Immunotherapy, Adoptive/methods [MESH] |Indoleamine-Pyrrole 2,3,-Dioxygenase/genetics [MESH] |Neoplasms/immunology/prevention & control/*therapy [MESH] |RNA Interference [MESH] |RNA, Small Interfering/genetics/therapeutic use [MESH]Engineering better immunotherapies via RNA interference (epmc).pdf DeepDyve Pubget Overpricing